{
    "paper_id": "b7f0706ed909bc556c930e04a022f3301f46094e",
    "metadata": {
        "title": "Supporting Information An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy",
        "authors": [
            {
                "first": "Thanigaimalai",
                "middle": [],
                "last": "Pillaiyar",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Bonn",
                    "location": {
                        "postCode": "D-53121",
                        "settlement": "Bonn",
                        "country": "Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "\u2225",
                "middle": [],
                "last": "Manojmanickam",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Chungnam National University",
                    "location": {
                        "postCode": "305-764",
                        "settlement": "Daejeon",
                        "country": "South Korea Corresponding Author"
                    }
                },
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Vigneshwarannamasivayam",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Bonn",
                    "location": {
                        "postCode": "D-53121",
                        "settlement": "Bonn",
                        "country": "Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "Yoshio",
                "middle": [],
                "last": "Hayashi",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tokyo University of Pharmacy and Life Sciences",
                    "location": {
                        "postCode": "192-0392",
                        "settlement": "Tokyo",
                        "country": "Japan"
                    }
                },
                "email": ""
            },
            {
                "first": "Sang-Hun",
                "middle": [],
                "last": "Jung",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Chungnam National University",
                    "location": {
                        "postCode": "305-764",
                        "settlement": "Daejeon",
                        "country": "South Korea Corresponding Author"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": ". The docked pose of compound 18 with 2GX4 Figure S2 . The crystal structure of compounds 40-43 complexed with SARS 3CL pro Figure S3 . The crystal structure of compound 44bound with SARS 3CL pro Figure S4 . The crystal structure complex of compound 45and SARS 3CL pro Figure S5 . The docked pose of compound 78into the binding pocket of SARS 3CL pro Figure S6 . The docked pose of compound 86in the binding pocket of SARS 3CL pro Figure S7 . The docked pose of compound 105in the binding pocket of SARS 3CL pro Figure S8 . The docked pose of compound 140 in the binding pocket of SARS 3CL pro Table 1 .Sequence comparison analysis of 3CL pro of Coronaviruses to the SARS-CoV 3CL pro Tor2 strain. Table 2 .A List of X-ray crystal structures of ligands with 3CL pro Figure S1 : The docked pose of compound 18 (green) into the binding pocket of SARS 3CL pro (PDB ID: 2GX4). 1 The key interacting amino acid Cys145 is highlighted in magenta and binding pocket in grey. ",
            "cite_spans": [
                {
                    "start": 872,
                    "end": 873,
                    "text": "1",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 43,
                    "end": 52,
                    "text": "Figure S2",
                    "ref_id": null
                },
                {
                    "start": 124,
                    "end": 133,
                    "text": "Figure S3",
                    "ref_id": null
                },
                {
                    "start": 196,
                    "end": 205,
                    "text": "Figure S4",
                    "ref_id": null
                },
                {
                    "start": 269,
                    "end": 278,
                    "text": "Figure S5",
                    "ref_id": null
                },
                {
                    "start": 351,
                    "end": 360,
                    "text": "Figure S6",
                    "ref_id": "FIGREF1"
                },
                {
                    "start": 431,
                    "end": 440,
                    "text": "Figure S7",
                    "ref_id": "FIGREF2"
                },
                {
                    "start": 512,
                    "end": 521,
                    "text": "Figure S8",
                    "ref_id": "FIGREF3"
                },
                {
                    "start": 594,
                    "end": 601,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 697,
                    "end": 704,
                    "text": "Table 2",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 765,
                    "end": 774,
                    "text": "Figure S1",
                    "ref_id": null
                }
            ],
            "section": "Table of contents"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Jacobs",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Grum-Tokars",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Turlington",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Saldanha",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Chase",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Eggler",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "S"
                    ],
                    "last": "Dawson",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "M"
                    ],
                    "last": "Baez-Santos",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Tomar",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Mielech",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "Baker",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "W"
                    ],
                    "last": "Lindsley",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Hodder",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mesecar",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Stauffer",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J. Med. Chem",
            "volume": "56",
            "issn": "",
            "pages": "534--546",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Turlington",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Chun",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Tomar",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Eggler",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Grum-Tokars",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Jacobs",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Daniels",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Dawson",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Saldanha",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Chase",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "M"
                    ],
                    "last": "Baez-Santos",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "W"
                    ],
                    "last": "Lindsley",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Hodder",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mesecar",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Stauffer",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Bioorg. Med. Chem. Lett",
            "volume": "23",
            "issn": "",
            "pages": "6172--6177",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Shimamoto",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hattori",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Kobayashi",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Teruya",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sanjoh",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Nakagawa",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Yamashita",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Akaji",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Bioorg. Med. Chem",
            "volume": "23",
            "issn": "",
            "pages": "876--890",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Dimerization of the SARS coronavirus 3CL protease is controlled through long-range interactions",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Barrila",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "The crystal structure of compounds 40-43 complexed with SARS 3CL pro . The compounds A) 41 (green, PDB ID:3SNE) B) 42 (cyan, PDB ID:3SNA) C) 43 (blue, PDB ID:3SNB) and D) 44 (brown, PDB ID:3SNC) shown in stick model and highlighted with their respective amino acids in the S2 pocket. The crystal structure of compound 44(brown) bound with SARS 3CL pro . The amino acids in the binding pocket (grey) with the important amino acids (cyan) are highlighted. The crystal structure complex of compound 45(blue) and SARS 3CL pro . The unique conformation of benzyloxy is shown in red circle, the amino acids in the binding pocket (grey) and covalent bonding of 45 with Cys145 (magenta) is highlighted. The docked pose of compound 78(magenta) into the binding pocket of SARS 3CL pro (PDBID: 1UK4). 3 The key interacting amino acids (cyan) are highlighted with the amino acids in the binding pocket (grey).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "The docked pose of compound 86(golden yellow) in the binding pocket of SARS 3CL pro (PDBID: 2Z3E).4  The key interacting amino acids Gln192 and Val186 (green) are highlighted with the amino acids in the binding pocket (grey).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "The docked pose of compound 105(blue) in the binding pocket of SARS 3CL pro (PDBID: 1UK4).3  The key interacting amino acids Glu166, Pro168, and Gln192 (magenta) are highlighted with the amino acids in the binding pocket (grey).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "The docked pose of compound 140 (cyan) in the binding pocket of SARS 3CL pro (PDBID: 1UK4). 3 Nitro group formed a hydrogen bond with side chains of Gly-143 and Cys145, and the 4-chloro phenyl ring was predicted to fit into the S2 pocket.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "A. H. -J.; Hsu, M. -C. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J. Med. Chem. 2006, 49, 4971-4980. (2) Zhu, L.; George, S.; Schmidt, M. F.; Al-Gharabli, S. I.; Rademann, J.; Hilgenfel. R. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Res. 2011, 92, 204-212. (3) Yang, H.; Yang, M.; Ding, Y.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.; Mo, L.; Ye, S.; Pang, H.; Gao, G. F.; Anand, K.; Bartlam, M.; Hilgenfeld, R.; Rao, Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. USA2003, 100, 13190-1315. (4) Ryu, Y. B.; Park, S.-J.; Kim, Y. M.; Lee, J. Y.; Seo, W. D.; Chang, J. S.; Park, K. H.; Rho, M.-C.; Lee, W. S. Biflavonoids from Torreyanucifera displaying SARS-CoV 3CLpro inhibition. Bioorg.Med.Chem. 2010, 18, 7940-7947 (5) Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J. R.; Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science2003, 300, , R.Y.; Tsui, W. H. W.; Lee, T. S. W.; Tanner, J. A.; Watt, R. M.; Hung, J. D.; Hu, L. H.; Chen, G. H.; Chen, Z. W.; Zhang, L. Q.; He, T.; Chan, K. H.; Tse, H.; To, A. P. C.; Ng, L. W. Y.; Wong, B. C. W.; Tsoi, H. W.; Yang, D.; Ho, D. D.; Yuen, K. Y. Identification of novel small-molecule inhibitors of severe acute respiratory syndromeassociated coronavirus by chemical genetics. Chem. Biol.2004, 11, 1293-1299. (7) Lee, C.-C.; Kuo, C.-J.; Hsu, M.-F.; Liang, P.-H.; Fang, J.-M.; Shie, J.-J.; Wang. A. H.-J. Structural basis of mercury-and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors. FEBS Lett.2007, 581, 5454-5458 (8) Yin, J.; Niu, C.; Cherney, M. M.; Zhang, J.; Huitema, C.; Eltis, L. D.; Vederas, J. C.; James, M.N.G. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase.J. Mol. Biol. 2007, 371, 1060-1074.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Sequence comparison analysis of 3CL pro of Coronaviruses to the SARS-CoV 3CL pro Tor2 strain.12",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "A List of X-ray crystal structures of ligand with proteases",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}